Surescripts

Overview

Surescripts is the dominant national health information network for U.S. prescription transactions, operating e-prescribing, electronic prior authorization (Touchless PA), Real-Time Prescription Benefit (RTPB), Medication History, and clinical interoperability workflows for ~1M prescribers and the vast majority of U.S. pharmacies, EHRs, and payers. Surescripts is owned by a consortium of pharmacy and PBM stakeholders alongside TPG Capital, which acquired a majority stake in October 2024 at a ~$1.8B valuation; NCPA, NACDS, Express Scripts (Cigna), and CVS Caremark retained minority equity, so PBM and chain-pharmacy co-ownership of the connecting infrastructure remains a structural feature buyers must diligence.

Surescripts is best read as the prescription-transaction backbone, not as a hub-services operator, a manufacturer-services platform, or a case-management vendor. The relevant manufacturer wedge is workflow placement inside prescriber tools, pharmacy routing, benefit transparency, touchless PA, and first-fill abandonment signals. RTPB’s display logic, shaped by PBM-owner formulary decisions, structurally surfaces generic or preferred-brand alternatives before the patient leaves the exam room — a critical implication for non-preferred-tier brands.

Reimbursement and PA Capability Model

The framework below standardizes how Rx Almanac evaluates reimbursement-prior-auth capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Surescripts is evaluated as the prescription-transaction backbone, not as a hub-services operator, a manufacturer-services platform, or a case-management vendor.

Capability	Buyer should compare	Surescripts readout
Electronic PA initiation and payer connectivity	ePA submission, payer integrations, plan-specific requirements, real-time decisioning, and transaction reach.	Core PA casework. Touchless PA reports an 18-second median approval; AmeriHealth’s 2025 ePA move from CoverMyMeds to Surescripts was the first public payer defection.
Benefits verification and coverage discovery	Eligibility, pharmacy/medical benefit checks, policy criteria, coverage route, and reimbursement path identification.	Core coverage workflow. E-prescribing routing, eligibility, and RTPB; 900K+ prescriber users with $77 average savings per standard Rx and $817 per specialty Rx reported.
Clinical documentation and appeals support	Document collection, criteria matching, appeal packets, peer-to-peer prep, and denial management.	Adjacent. Surescripts is transaction infrastructure; pair with a hub, appeals vendor, or specialty pharmacy for documentation and appeals operations.
Provider workflow integration	EHR, portal, fax, call, pharmacy, and practice-management workflows that reduce office burden.	Core network reach. National coverage across prescriber, pharmacy, EHR, and payer endpoints is the structural moat.
Automation, AI, and queue prioritization	AI agents, rules engines, form completion, status retrieval, queue triage, and exception handling.	Adjacent. Touchless PA automates inside the network; AI-agent tooling is not the primary product story.
Reporting, status visibility, and policy intelligence	Case status, payer trend reporting, denial reasons, turnaround metrics, and policy-change intelligence.	Core reporting layer. RTPB surfaces formulary status and alternatives to prescribers in real time; the data asset on PA friction and first-fill abandonment is unmatched in scale.

Buyer Fit

• Shortlist when: Include Surescripts when access strategy depends on placement inside prescriber tools, pharmacy routing, benefit transparency, touchless PA, or first-fill abandonment signals.
• Best-fit buyers: Pharma manufacturers, biotech launch teams, payers, providers, and pharmacy networks evaluating prescription-transaction infrastructure rather than an outsourced hub or BV operations.
• Less ideal fit: Programs whose primary need is hub case management, outsourced nurse support, appeals operations, fulfillment, or dispensing.
• Commercial fit: Pricing is not publicly standardized; expect RFP-led scope with explicit data-feed, integration, and governance terms.
• Governance fit: PBM and chain-pharmacy co-ownership plus TPG majority creates structural channel-conflict and display-logic implications; diligence formulary placement and RTPB display rules for non-preferred-tier brands.
• Coverage diligence: Confirm payer plan coverage post-AmeriHealth defection from CoverMyMeds, EHR-specific Touchless PA reach, RTPB display logic, data rights, and clinical-review boundaries.

Differentiators

• National transaction backbone: The dominant U.S. prescription-transaction network; majority of e-prescribing volume flows through Surescripts.
• Touchless PA at 18-second median approval: The fastest ePA path inside the network for plans that have adopted it.
• RTPB at 1B+ uses in 2025: 900K+ prescriber users; $77 average savings per standard Rx and $817 per specialty Rx — and the display logic is structurally adverse to non-preferred-tier brands.
• PA-friction and adherence data depth: Medication History and ePA data together represent the most comprehensive U.S. dataset on PA friction and fill-rate signals.
• QHIN designation and HITRUST r2: TEFCA designation and HITRUST r2 across E-Prescribing, Touchless PA, and Master Patient Index are concrete compliance anchors.

RFP Questions

• Which payer plans support Touchless PA for the product, especially after AmeriHealth’s 2025 move from CoverMyMeds?
• How does RTPB display the product against generic and therapeutic alternatives at point-of-prescribing, and what governance controls that surface?
• What ePA, e-prescribing, RTPB, and Medication History data can the manufacturer receive, and where are PBM-owner data-rights and channel-conflict boundaries?
• How does CLEAR identity verification integrate into provider workflows for the product’s expected prescriber mix?
• What clinical-criteria, denial-reason, and turnaround reporting flows back to hub, specialty pharmacy, FRM, and manufacturer teams?
• How does the TPG ownership transition change product roadmap, pricing, and PA-automation investment priorities?

Recent Activity

• 2026-05 - Current Surescripts materials add direct life-sciences, patient-access-vendor, electronic benefit verification, and Intelligent Prior Authorization surfaces while PBM co-ownership diligence remains central.

• 2025 - RTPB crossed 1B uses with 900K+ prescriber users; $77 average savings per standard Rx and $817 per specialty Rx reported.

• 2025-08 - AmeriHealth discontinued CoverMyMeds ePA in favor of Surescripts; first public payer defection.

• 2025-04 - QHIN designation under TEFCA; HITRUST r2 certification across E-Prescribing, Touchless PA, and Master Patient Index; CLEAR identity-verification partnership boosted provider verification success from 41% to 80%.

• 2025-02 - Touchless Prior Authorization launched at 18-second median approval; update late 2025.

• 2024-10 - TPG Capital acquired a majority stake; NCPA, NACDS, Express Scripts (Cigna), and CVS Caremark retained minority equity.